Compositions that can improve symptoms of intestinal inflammation and restore key bacterial populations

Abstract

The present application provides a composition for improving intestinal inflammatory symptoms and restoring key flora. Specifically, the present application provides an application of a composition in the preparation of a product for improving intestinal inflammatory symptoms and restoring key flora, wherein the composition comprises 2'-fucosyllactose and osteopontin, and the mass ratio of 2'-fucosyllactose to osteopontin is 1:(0.017-1.3). The present application also provides a food containing the composition, and an application of the composition or the food in the preparation of a product for improving intestinal inflammatory symptoms and restoring key flora.

Description

Technical Field

[0001] This invention belongs to the field of nutritional composition technology, specifically relating to a nutritional composition that can improve intestinal inflammation symptoms and restore key flora and related applications. Background Technology

[0002] The first 1000 days of life are a critical window of opportunity for infant development. The dynamic development of the gut microbiota and the gut immune system complement each other. The gut is not only an important site for the digestion and absorption of nutrients, but also a vital barrier against external pathogens. Maintaining gut homeostasis and enhancing gut immune function are crucial for overall health. After birth, infants are highly susceptible to gastrointestinal infections, inflammation, and allergic diseases due to their immature digestive and immune functions and the unstable formation and development of their gut microbiota. Breast milk is the first food infants encounter. It is rich in nutrients, immune-active components, growth factors, and oligosaccharides. These components in breast milk provide immune support and promote the maturation of the intestinal barrier function, while also providing nutrients for beneficial bacteria such as Bifidobacteria and Lactobacillus, helping to create a healthy gut microbiota and ensuring intestinal health. The literature shows that the infant gut microbiota is closely related to the development of the infant and the formation of the immune system. Establishing a healthy gut microbiota in the first 1000 days of life is of great importance to the development and maturation of the intestinal mucosal immune system and the systemic immune system. The structure and relative abundance of the gut microbiota in early life can affect the probability of developing diseases later in life.

[0003] Furthermore, a large number of foundational species exist in the healthy human body, playing a crucial and indispensable role in the species and functional diversity of the gut microbiota. The specific composition of the foundational microbiota in infants and young children still needs further clarification. Some literature indicates that the infant gut microbiota is mainly composed of five phyla: Actinobacteria, Bacteroidetes, Firmicutes, Proteobacteria, and Verrucomicrobia. Numerous studies have shown that the main difference between the gut microbiota of diseased and healthy individuals lies in the relative abundance of Firmicutes and the relative abundance of Proteobacteria in the gut of diseased individuals.

[0004] Providing infants and young children with a nutritional composition that can prevent and / or improve symptoms of intestinal inflammation and restore key flora is essential for their healthy growth. Summary of the Invention

[0005] One object of the present invention is to provide a composition that can improve symptoms of intestinal inflammation and restore key flora.

[0006] Another object of the present invention is to provide products comprising the said composition, such as food products.

[0007] Another object of the present invention is to provide the relevant applications of the said composition or food in improving intestinal inflammatory symptoms and restoring key flora.

[0008] On one hand, the present invention provides the use of a composition in the preparation of a product that improves intestinal inflammation symptoms and restores key flora, wherein the composition comprises 2'-fucosylated lactose and osteopontin, and the mass ratio of 2'-fucosylated lactose to osteopontin is 1:(0.017-1.3).

[0009] 2'-Fucosyllactose (2'-FL or 2-FL) is a trisaccharide formed from fucose and lactose, and is a representative substance of fucosyl oligosaccharides. Commercially available fucosyl lactose is usually prepared through microbial fermentation and has the same structure as oligosaccharides found in human milk.

[0010] Osteopontoxin (OPN) is a secreted, phosphorylated integrin-binding protein and an atypical immunomodulatory factor whose role in regulating the immune response has been clearly established. OPN can promote cell survival and inhibit apoptosis, which plays a key role in the protection of the intestinal mucosa.

[0011] On the other hand, the present invention also provides a composition for improving intestinal inflammation symptoms and restoring key flora, the composition comprising 2'-fucosylated lactose and osteopontin, wherein the mass ratio of 2'-fucosylated lactose to osteopontin is 1:(0.017-1.3).

[0012] On the other hand, the present invention also provides a product for improving intestinal inflammation symptoms and restoring key flora, the product comprising the composition described above, namely containing 2'-fucosylated lactose and osteopontin, wherein the mass ratio of 2'-fucosylated lactose to osteopontin is 1:(0.017-1.3).

[0013] According to a specific embodiment of the present invention, in the composition or product of the present invention, the mass ratio of 2'-fucosylated lactose to osteopontin is 1:(0.1-1.3).

[0014] According to a specific embodiment of the present invention, in the composition or product of the present invention, the mass ratio of 2'-fucosylated lactose to osteopontin is 1:(0.2-1.3).

[0015] According to a specific embodiment of the present invention, in the composition or product of the present invention, the mass ratio of 2'-fucosylated lactose to osteopontin is 1:(0.25-1.3).

[0016] According to a specific embodiment of the present invention, the improvement of intestinal inflammation symptoms and restoration of key flora includes one or more of the following:

[0017] Improves weight loss caused by intestinal inflammation;

[0018] Improves intestinal damage caused by inflammatory response;

[0019] Reduce the increase in serum myeloperoxidase (MPO) activity caused by intestinal inflammation;

[0020] Reduce the increase in serum diamine oxidase (DAO) levels caused by intestinal inflammation;

[0021] Increase the level of goblet cells in the gut (improve the decrease in circular cell levels caused by intestinal inflammation);

[0022] Improve intestinal barrier function;

[0023] Enhance the intestinal physical and / or mucus barrier;

[0024] Increases the expression level of intestinal mucin (improves the decrease in mucin levels caused by intestinal inflammation);

[0025] Increase the expression level of intestinal tight junction proteins (improve the decrease in tight junction protein levels caused by intestinal inflammation);

[0026] Maintaining intestinal cellular immune homeostasis;

[0027] Improves the imbalance of intestinal immune cells caused by inflammatory response;

[0028] Increase the expression of CD4+ T cells in the gut;

[0029] Reduced expression of CD8+ T cells in the gut;

[0030] Increase the CD4+ / CD8+ T cell ratio in the gut;

[0031] Enhance the diversity and / or richness of the gut microbiota;

[0032] To restore the gut microbiota dysbiosis or reduced diversity caused by inflammation or antibiotics;

[0033] It improves the reduction in gut microbiota caused by intestinal mucosal immune damage;

[0034] Increase the abundance of the gut bacteria genera Muribaculaceae and / or Lactobacillus;

[0035] Reduce the abundance of Escherichia-Shigella and / or Alloprevotella in the gut.

[0036] According to a specific embodiment of the present invention, the product is a nutritional supplement.

[0037] According to a specific embodiment of the present invention, the product is a food product; preferably, the food product is infant formula, toddler formula, or infant formula for special medical purposes.

[0038] According to a specific embodiment of the present invention, the amount of the composition added to food is 0.5-1.8g / 100g of dry matter, calculated based on the 2'-fucosylated lactose contained therein.

[0039] According to a specific embodiment of the present invention, the amount of the composition added to food is 0.6-1.6g / 100g of dry matter, calculated based on the 2'-fucosylated lactose contained therein.

[0040] According to a specific embodiment of the present invention, the amount of the composition added to food is 0.7-1.4g / 100g of dry matter, calculated based on the 2'-fucosylated lactose contained therein.

[0041] According to a specific embodiment of the present invention, the amount of the composition added to food is 0.8-1.3g / 100g of dry matter, calculated based on the 2'-fucosylated lactose contained therein.

[0042] In some specific embodiments of the present invention, the amount of the composition added to the food is calculated based on the 2'-fucosylated lactose contained therein as 0.6-0.7g / 100g dry matter, 0.8-0.9g / 100g dry matter, 1.0-1.1g / 100g dry matter, 1.2-1.3g / 100g dry matter, 1.4-1.5g / 100g dry matter, or 1.6-1.7g / 100g dry matter.

[0043] According to a specific embodiment of the present invention, the food is milk powder or liquid milk.

[0044] In some specific embodiments of the present invention, the food product of the present invention is milk powder, which can be prepared by adding / adjusting 2'-fucosylated lactose and osteopontin to a basic formula powder. After preparing the milk powder of the present invention, the content of 2'-fucosylated lactose and osteopontin can be determined using conventional methods in the art, such as high-performance liquid chromatography (HPLC). The basic formula powder is not particularly limited in the present invention, as long as it is a commonly used milk powder formula in the art. For example, the basic formula powder can be ordinary infant formula or toddler formula. As a specific example, the basic formula powder of the present invention can use animal-derived milk powder as the main raw material, and can be further fortified with one or more of whey powder, vitamins, minerals, etc. The animal-derived milk powder can be cow's milk powder or goat's milk powder.

[0045] In the food products of this invention, the amounts of each substance should meet the relevant standard requirements.

[0046] On the other hand, the present invention also provides the use of the composition in the preparation of formulations having one or more of the following functions:

[0047] Improves weight loss caused by intestinal inflammation;

[0048] Improves intestinal damage caused by inflammatory response;

[0049] Reduce the increase in serum myeloperoxidase (MPO) activity caused by intestinal inflammation;

[0050] Reduce the increase in serum diamine oxidase (DAO) levels caused by intestinal inflammation;

[0051] Increase the level of goblet cells in the gut;

[0052] Improve intestinal barrier function;

[0053] Enhance the intestinal physical and / or mucus barrier;

[0054] Increase the expression level of intestinal mucin;

[0055] Increase the expression level of intestinal tight junction proteins;

[0056] Maintaining intestinal cellular immune homeostasis;

[0057] Improves the imbalance of intestinal immune cells caused by inflammatory response;

[0058] Increase the expression of CD4+ T cells in the gut;

[0059] Reduced expression of CD8+ T cells in the gut;

[0060] Increase the CD4+ / CD8+ T cell ratio in the gut;

[0061] Enhance the diversity and / or richness of the gut microbiota;

[0062] To restore the gut microbiota dysbiosis or reduced diversity caused by inflammation or antibiotics;

[0063] It improves the reduction in gut microbiota caused by intestinal mucosal immune damage;

[0064] Increase the abundance of the gut bacteria genera Muribaculaceae and / or Lactobacillus;

[0065] Reduce the abundance of Escherichia-Shigella and / or Alloprevotella in the gut;

[0066] The composition comprises 2'-fucosylated lactose and osteopontin, wherein the mass ratio of 2'-fucosylated lactose to osteopontin is 1:(0.017-1.3), preferably 1:(0.1-1.3), more preferably 1:(0.2-1.3), and even more preferably 1:(0.25-1.3).

[0067] According to a specific embodiment of the present invention, the preparation can be a laboratory preparation or a pharmaceutical preparation.

[0068] According to a specific embodiment of the present invention, the application described herein is for non-therapeutic purposes.

[0069] The composition of the present invention containing 2'-fucosylated lactose and osteopontin can improve intestinal inflammation symptoms in infants and young children and restore key flora, which is beneficial to the healthy growth of infants and young children. Attached Figure Description

[0070] Figure 1 This shows the changes in body weight of rats in each group 6 hours after LPS treatment in a specific experiment of this invention.

[0071] Figure 2 This shows the weight loss of rats in each group 6 hours after LPS treatment in a specific experiment of the present invention.

[0072] Figure 3 This invention demonstrates the MPO activity in the serum of rats in each group during a specific experiment.

[0073] Figure 4 This shows the serum DAO levels of rats in each group during a specific experiment of this invention.

[0074] Figure 5 This invention demonstrates the effect of each group on the number of goblet cells in the intestine in a specific experiment.

[0075] Figures 6A-6D The expression of mucin and tight junction protein in the colon tissue of rats in each group is shown in a specific experiment of the present invention.

[0076] Figures 7A-7C The expression of immune cells in each group in a specific experiment of the present invention is shown respectively.

[0077] Figure 8 This illustrates the effect of different groups on the number of OUTs in a specific experiment of the present invention.

[0078] Figure 9 This invention demonstrates the effect of different groups on the composition of the gut microbiota in a specific experiment. Detailed Implementation

[0079] Before further describing specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terminology used in the embodiments of the present invention is for describing specific embodiments and not for limiting the scope of protection of the present invention.

[0080] When numerical ranges are given in the embodiments, it should be understood that, unless otherwise stated in the present invention, the two endpoints of each numerical range and any value between the two endpoints may be selected.

[0081] Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art.

[0082] In addition to the specific methods, equipment, and materials used in the embodiments, based on the knowledge of those skilled in the art and the description of this invention, any prior art methods, equipment, and materials similar to or equivalent to those described, equipment, and materials in the embodiments of this invention can be used to implement this invention.

[0083] Unless otherwise stated, the experimental methods, detection methods and preparation methods disclosed in this invention all adopt conventional techniques in this technical field.

[0084] In the examples, all reagents and test substances used were commercially available through conventional channels.

[0085] Experimental study on the efficacy of nutritional compositions in improving intestinal inflammation symptoms and restoring key flora.

[0086] This study collected fecal samples from healthy infants aged 3-6 months and used fecal transplantation (FPT) to construct a humanized infant gut microbiota rat model. The rats were divided into five groups: a normal control group (NC group, administered 1 mL PBS daily by gavage), a model group (LPS group, administered 1 mL PBS daily by gavage), a 2'-FL group (administered 1 mL 2'-FL daily by gavage), an OPN group (administered 1 mL OPN daily by gavage), and a 2'-FL+OPN group (administered 1 mL of a mixed solution of 2'-FL and OPN daily by gavage), with 12 rats in each group. After 14 days of gavage, the rats in each group were weighed. Except for the NC control group, the other four groups received LPS intervention (8 mg / kg body weight) and were observed for another 6 hours before being weighed again. The gavage concentration of 2'-FL was 443 mg / kg body weight, and the gavage concentration of OPN was 300 mg / kg body weight; the mixed solution dosage was the sum of the two. After the animal experiments were completed, blood samples, as well as terminal ileum and colon tissues from rats were collected. The MPO activity and DAO content in rat serum were detected using an ELISA kit (Solepro, BC5715) according to the instructions.

[0087] Colon tissue was homogenized with liquid nitrogen and total RNA was extracted. The extracted RNA was reverse transcribed into cDNA using a reverse transcription kit (Qiagen, 51340). The expression levels of MUC2, ZO-1, Claudin-1 and Claudin-2 in colon tissue were measured using PCR.

[0088] The expression of CD4 and CD8 in the rat intestine was assessed by immunofluorescence analysis, and the CD4 / CD8 ratio was calculated.

[0089] Finally, total DNA was extracted using a genomic DNA extraction kit and sequenced using an Illumina MiSeq high-throughput sequencer. Based on the barcode and PCR primer sequences, data from each sample were separated from the sequenced data. After removing the barcode and primer sequences, the sequences were assembled using FLASH software. The gut microbiota composition of each group was then obtained.

[0090] Group information is shown in Table 1:

[0091] Table 1

[0092] Group Details NC Group Normal rats were administered PBS by gavage, without LPS treatment. LPS Group The model animal group was administered PBS by gavage and treated with LPS. 2'-FL Monotherapy group, administered 2'-FL by gavage, with LPS treatment OPN Monotherapy group, administered OPN via gavage, with LPS treatment 2'FL+OPN 2'FL+OPN, a gavage composition with LPS treatment

[0093] Experimental results:

[0094] 1. Changes in body weight of rats before and after LPS treatment in each group

[0095] All experimental rats were weighed before the start of LPS injection, and there were no significant differences between the groups. The results are as follows: Figure 1The initial body weight is shown in the figure. Six hours after LPS injection, the body weight of rats in the injection groups (LPS group, 2'-FL group, OPN group, and 2'-FL+OPN group) was significantly lower than that of uninjected rats (NC group), as shown in the figure. Figure 2 As shown.

[0096] 2. Serum myeloperoxidase (MPO) activity in each group

[0097] Myeloperoxidase (MPO) in serum is a leukocyte enzyme mainly secreted by activated macrophages, neutrophils and monocytes. When the body is subjected to oxidative stress, such as infection or fever, the body can release a large amount of MPO, which produces oxygen free radicals, promotes the oxidation of low-density lipoprotein in the body, and promotes the occurrence and development of inflammatory response.

[0098] The results are as follows Figure 3 As shown, compared with the NC group, the LPS group showed a significant increase in serum MPO activity after LPS treatment (p<0.05), indicating that LPS treatment increases the level of intestinal inflammation. Compared with the LPS group, the serum MPO activity of the 2'-FL, OPN, and 2'-FL+OPN groups was significantly reduced. The 2'-FL+OPN group showed a better reduction in serum MPO activity compared with the other two groups, with no significant difference from the NC group. The combination showed a certain synergistic effect, indicating that the 2'-FL+OPN group can alleviate the damage of inflammation to the intestine by reducing MPO activity.

[0099] 3. Serum diamine oxidase (DAO) levels in each group

[0100] Diamine oxidase (DAO) is a structural enzyme specifically present in the epithelial cells of the small intestinal mucosa. It is a key enzyme catalyzing histamine oxidation, with over 90% found in the small intestinal mucosa. The main function of DAO is to control intestinal mucosal proliferation, and its activity is closely related to the metabolism of intestinal mucosal epithelial cells. When the intestine is damaged or inflamed, DAO synthesis at the damaged site increases, and DAO subsequently enters the bloodstream. DAO is stable in serum, thus reflecting the state of intestinal barrier damage and repair.

[0101] like Figure 4 As shown, compared with the NC group, the serum DAO level of rats in the LPS group was significantly increased, indicating that the intestinal barrier of rats was more severely damaged. Compared with the LPS model group, the serum DAO level of rats in the intervention group was significantly reduced, indicating that their intestinal damage was protected to some extent. The 2'-FL+OPN composition was more effective than 2'-FL and OPN monomers in reducing the DAO increase caused by LPS treatment, and there was no significant difference compared with the NC group, showing a certain synergistic effect.

[0102] 4. Intestinal goblet cell level

[0103] The intestinal epithelium is mainly composed of four types of cells: absorptive cells, goblet cells, Paneth cells, and endocrine cells. These cells are constantly renewed, ensuring the integrity of the intestinal epithelium. Studies have shown that changes in the differentiation and secretory function of goblet cells can lead to alterations in the composition of the mucus layer, playing a crucial role in the development and progression of intestinal diseases.

[0104] The results are as follows Figure 5 As shown, the LPS group exhibited epithelial cell shedding, inflammatory cell infiltration, and a decrease in goblet cells in the intestine. In contrast, the intervention groups (2'-FL, OPN, and 2'-FL+OPN) showed significant improvements in intestinal pathology and goblet cell count. The goblet cell count in the 2'-FL+OPN group was higher than that in the LPS and 2'-FL / OPN monotherapy groups, indicating that 2'-FL and OPN have a certain effect in preventing tissue damage caused by LPS, and the combination of 2'-FL and OPN is more effective than either 2'-FL or OPN alone.

[0105] 5. Gene expression levels of ileal mucin and tight junction protein

[0106] Mucins, primarily composed of protein molecules, glycosyl compounds, amino acid residue modifications, and metal ions, are a major component of the intestinal mucosal barrier. Members of the intestinal mucin family, such as mucin 1 (MUCl), mucin 2 (MUC2), mucin 5B (MUC5B), and mucin 13 (MUCl3), are expressed in the intestine and perform different functions. MUC2, composed of 5100 amino acids, provides a protective barrier between the intestinal epithelial surface and the intestinal lumen. In addition to the mucosal barrier, tight junctions are composed of various ocludin, cladding, and zonal occludens (ZOs). These three types of proteins, along with the actin cytoskeleton, connect adjacent cells to form the epithelial barrier.

[0107] The mRNA expression levels of MUC2, Claudin-1, Claudin-2, and ZO-1 reflected the function of the intestinal barrier, as shown in the results. Figures 6A-6DAs shown, compared with the NC group, the mRNA expression level in the LPS group was significantly reduced (P<0.05); the 2'-FL, OPN, and 2'-FL+OPN groups significantly altered this result, upregulating the mRNA expression levels of MUC2, Claudin-1, Claudin-2, and ZO-1. In particular, in the 2'-FL+OPN group, the mRNA expression levels of MUC2, Claudin-1, Claudin-2, and ZO-1 were significantly increased, showing the most significant effect among all intervention groups, even showing no significant difference compared to the NC group (Claudin-1), indicating a certain synergistic effect.

[0108] 6. Expression of immune cells in each group

[0109] See the expression of immune cells in each group. Figures 7A-7C Compared with the NC group, CD4+ expression in the intestines of rats in the LPS group was significantly decreased, while CD4+ T cell expression was significantly increased in the 2'-FL, OPN, and 2'-FL+OPN groups. Compared with the NC group, CD8+ T cell expression was significantly increased in the LPS group, while CD8+ T cell expression was significantly decreased in the 2'-FL, OPN, and 2'-FL+OPN groups. The CD4+ / CD8+ T cell ratio showed that the CD4+ / CD8+ T cell ratio was significantly decreased in the LPS group compared with the NC control group (P<0.05), indicating an imbalance in the proportion of intestinal immune cells and impaired immune function in rats after LPS treatment. The CD4+ / CD8+ ratio was significantly increased in the 2'-FL, OPN, and 2'-FL+OPN groups, especially in the 2'-FL+OPN group, which showed the most significant increase in the CD4+ / CD8+ T cell ratio, demonstrating a certain synergistic effect.

[0110] The effects of the combination of 7.2'-FL and OPN on gut microbiota

[0111] This embodiment further investigates the effects of the 2'-FL+OPN composition on the gut microbiota of infants and young children.

[0112] like Figure 8As shown, the NC group had significantly more unique OTUs than the LPS group, indicating that LPS treatment significantly reduced the diversity of gut microbiota in rats. The 2'-FL+OPN group showed some recovery in OTU numbers, suggesting that the 2'-FL+OPN group can significantly improve the reduction in gut microbiota caused by intestinal mucosal immune damage. Table 1 presents the results of α-diversity. The results show that compared with the NC group, the LPS group had significantly lower observed species index, chao1 index, shannon index, and simpson index. The 2'-FL+OPN group showed significantly higher levels of all four indices compared to the LPS group, with no significant difference compared to the NC group. These results indicate that 2'-FL+OPN can significantly improve both the diversity and richness of the gut microbiota community.

[0113] Table 2 shows the results of α-diversity. The results show that compared with the NC group, the LPS group had significantly lower observed species index, chao1 index, shannon index and simpson index. Compared with the LPS group, the 2'-FL+OPN group had significantly higher all four indices. The results indicate that 2'-FL+OPN can significantly improve the diversity and richness of the microbial community.

[0114] Table 2. α-diversity analysis of each group

[0115] NC LPS 2'-FL+OPN chao1 618.98±48.23 472.70±15.60 621.86±10.93 observed_species 500.70±29.87 381.90±9.75 529.40±4.87 shannon 5.39±0.08 4.43±0.19 5.43±0.04 simpson 0.93±0.01 0.88±0.01 0.94±0.01

[0116] The composition of the gut microbiota was analyzed using 16S sequencing. The results of the microbiota composition analysis are shown in [link to analysis]. Figure 9The results showed that, compared with the NC control group, the abundance of *Lactobacillus* and *Muribaculaceae* in the LPS group decreased significantly by 9.09% and 8.11%, respectively, while the abundance of *Escherichia-Shigella* and *Alloprevotella* increased significantly by 7.15% and 11.14%, respectively. In the 2'-FL+OPN group, *Lactobacillus* increased significantly by 10.12%, *Muribaculaceae* increased significantly by 3.87%, *Alloprevotella* decreased significantly by 21.11%, and *Escherichia-Shigella* decreased by 2.01%. Changes in other genera included *Eubacterium coprostanoligenes*, *Romboutsia*, *Lachnoclostridium*, and *Streptococcus*, but the changes were small or insignificant. These changes indicate that the 2'-FL+OPN group successfully improved the structure of the gut microbiota compared to the LPS model group, particularly by reducing the abundance of some potentially harmful genera, such as Shigella and Alloprevotella, and increasing the abundance of some potentially beneficial genera, such as Lactobacillus and Muribacaceae. Other genera changes included minor adjustments, making the gut microbiota structure of the 2'-FL+OPN group closer to that of the NC control group.

[0117] The above description of the embodiments is provided to enable those skilled in the art to understand and use the invention. It will be apparent to those skilled in the art that various modifications can be made to these embodiments, and the general principles described herein can be applied to other embodiments without inventive effort. Therefore, the present invention is not limited to the above embodiments, and any improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the invention should be within the protection scope of the present invention.

Claims

1. The use of a composition in the preparation of a product that improves intestinal inflammatory symptoms and restores key flora, wherein, The composition comprises 2'-fucosylated lactose and osteopontin, wherein the mass ratio of 2'-fucosylated lactose to osteopontin is 1:(0.017-1.3).

2. The application according to claim 1, wherein, In the composition, the mass ratio of 2'-fucosylated lactose to osteopontin is 1:(0.1-1.3); Preferably, the mass ratio of 2'-fucosylated lactose to osteopontin is 1:(0.2-1.3); Preferably, the mass ratio of 2'-fucosylated lactose to osteopontin is 1:(0.25-1.3).

3. The application according to claim 1 or 2, wherein, The improvement of intestinal inflammation symptoms and restoration of key flora include one or more of the following: Improves weight loss caused by intestinal inflammation; Improves intestinal damage caused by inflammatory response; Reduce the increase in serum myeloperoxidase (MPO) activity caused by intestinal inflammation; Reduce the increase in serum diamine oxidase (DAO) levels caused by intestinal inflammation; Increase the level of goblet cells in the gut (improve the decrease in circular cell levels caused by intestinal inflammation); Improve intestinal barrier function; Enhance the intestinal physical and / or mucus barrier; Increases the expression level of intestinal mucin (improves the decrease in mucin levels caused by intestinal inflammation); Increase the expression level of intestinal tight junction proteins (improve the decrease in tight junction protein levels caused by intestinal inflammation); Maintaining intestinal cellular immune homeostasis; Improves the imbalance of intestinal immune cells caused by inflammatory response; Increase the expression of CD4+ T cells in the gut; Reduced expression of CD8+ T cells in the gut; Increase the CD4+ / CD8+ T cell ratio in the gut; Enhance the diversity and / or richness of the gut microbiota; To restore the gut microbiota dysbiosis or reduced diversity caused by inflammation or antibiotics; It improves the reduction in gut microbiota caused by intestinal mucosal immune damage; Increase the abundance of the gut bacteria genera Muribaculaceae and / or Lactobacillus; Reduce the abundance of Escherichia-Shigella and / or Alloprevotella in the gut.

4. The application according to any one of claims 1-3, wherein, The product in question is a nutritional supplement.

5. The application according to any one of claims 1-3, wherein, The product is a food product; preferably, the food product is infant formula, toddler formula, or infant formula for special medical purposes.

6. The application according to claim 5, wherein, The amount of the composition added to food is 0.5-1.8g / 100g of dry matter, calculated based on the 2'-fucosylated lactose contained therein.

7. The application according to claim 6, wherein, The food product is milk powder or liquid milk.

8. A composition for improving intestinal inflammation symptoms and restoring key flora, the composition comprising 2'-fucosylated lactose and osteopontin, wherein the mass ratio of 2'-fucosylated lactose to osteopontin is 1:(0.017-1.3); preferably, the mass ratio of 2'-fucosylated lactose to osteopontin in the composition is 1:(0.1-1.3), more preferably 1:(0.2-1.3), and even more preferably 1:(0.25-1.3).

9. A food for improving symptoms of intestinal inflammation and restoring key flora, said food comprising 2'-fucosylated lactose and osteopontin, wherein the mass ratio of 2'-fucosylated lactose to osteopontin is 1:(0.017-1.3); Preferably, the amount of 2'-fucosylated lactose added to the food is 0.5-1.8g / 100g of dry matter. Preferably, the mass ratio of 2'-fucosylated lactose to osteopontin in the composition is 1:(0.1-1.3), more preferably 1:(0.2-1.3), and even more preferably 1:(0.25-1.3).

10. Use of a composition in the preparation of formulations having one or more of the following functions: Improves weight loss caused by intestinal inflammation; Improves intestinal damage caused by inflammatory response; Reduce the increase in serum myeloperoxidase (MPO) activity caused by intestinal inflammation; Reduce the increase in serum diamine oxidase (DAO) levels caused by intestinal inflammation; Increase the level of goblet cells in the gut (improve the decrease in circular cell levels caused by intestinal inflammation); Improve intestinal barrier function; Enhance the intestinal physical and / or mucus barrier; Increases the expression level of intestinal mucin (improves the decrease in mucin levels caused by intestinal inflammation); Increase the expression level of intestinal tight junction proteins (improve the decrease in tight junction protein levels caused by intestinal inflammation); Maintaining intestinal cellular immune homeostasis; Improves the imbalance of intestinal immune cells caused by inflammatory response; Increase the expression of CD4+ T cells in the gut; Reduced expression of CD8+ T cells in the gut; Increase the CD4+ / CD8+ T cell ratio in the gut; Enhance the diversity and / or richness of the gut microbiota; To restore the gut microbiota dysbiosis or reduced diversity caused by inflammation or antibiotics; It improves the reduction in gut microbiota caused by intestinal mucosal immune damage; Increase the abundance of the gut bacteria genera Muribaculaceae and / or Lactobacillus; Reduce the abundance of Escherichia-Shigella and / or Alloprevotella in the gut; The composition comprises 2'-fucosylated lactose and osteopontin, wherein the mass ratio of 2'-fucosylated lactose to osteopontin is 1:(0.017-1.3); preferably, the mass ratio of 2'-fucosylated lactose to osteopontin in the composition is 1:(0.1-1.3), more preferably 1:(0.2-1.3), and even more preferably 1:(0.25-1.3).

Images